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A B S T R A C T
Primary chondrosarcoma is a rare malignant tumor. The five types of chondrosarcomas are: central, peripheral,
mesenchymal, differentiated and clear cell. The classic chondrosarcomas are central (arising within a bone) or periph-
eral (arising from the surface of a bone). We describe a patient with central chondrosarcoma of the humerus who under-
went surgery and only two weeks later presented with multiple metastases of the lung and small pulmonary tumor embo-
lisms mimicking bilateral pneumonic infiltrates. Therefore, such a fulminant course of central chondrosarcoma, which
is not described so far, must be taken into consideration during the treatment of patients with primary chondrosarcoma.
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Introduction
Chondrosarcoma (CS) is the second most common
primary malignant spindle cell tumor of bone1. Chondro-
sarcomas form a heterogeneous group of tumors whose
basic neoplastic tissue is cartilaginous without evidence
of direct osteoid formation2. Occasionally, bone forma-
tion occurs from differentiation of cartilage. If evidence
is found of direct osteoid or bone production, the lesion is
classified as an osteosarcoma. The five types of chondro-
sarcomas are central, peripheral, mesenchymal, differen-
tiated and clear cell1,3. The classic chondrosarcomas are
central (arising within a bone) or peripheral (arising
from the surface of a bone). The other three are variants
and have distinct histologic and clinical characteristics.
Both central and peripheral chondrosarcomas can arise
as primary tumors or secondary to underlying neoplasm.
Seventysix percent of primary chondrosarcomas arise
centrally1,3,4. Secondary chondrosarcomas most often ari-
se from benign cartilage tumors. The multiple forms of
benign osteochondromas or enchondromas have a higher
rate of malignant transformation than the correspond-
ing solitary lesions4,5. Markers of cell differentiation, ac-
tivation, genetics and cell signaling may offer important
prognostic information6–8.
We describe a central type of chondrosarcoma arising
within humerus with unusual, fulminant course. Multiple
pulmonary metastases were developed only two weeks
after surgery mimicking pneumonic infiltrates. The pa-
tient died ten days later from subacute respiratory and
cardial insufficiency. Post mortem pathohistology sho-
wed multiple tumor emboli of the lungs accompanied by
multiple tumor emboli of the pulmonary artery.
Case Report
A 38-year-old-man was admitted to the orthopedic
clinic because of pain in the right shoulder. The X-ray re-
vealed radiological suspicion of the tumor of the right hu-
merus. Fine needle aspiration biopsy was performed, but
material was inadequate for cytological analysis. There-
fore an open biopsy was performed. Pathohystological di-
agnosis was CS grade I. All the laboratory findings and
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chest radiography at this time were normal (Figure 1).
After that the patient underwent surgery – the tumor
was extirpated, arthrodesis of the right humeroscapular
joint and spongioplastic of the humerus with homotrans-
plantations was made. Postoperative patohystological di-
agnosis was CS grade II (Figure 2). Two weeks after the
surgery the patient become high febrile with productive
cough and dyspnea. The laboratory analysis showed leko-
cytosis of 11.3  109/L (normal range = NR 4–9  109/L),
elevated sedimentation rate 115 (NR 2–10 mm/h), C re-
active protein 150 mg/L (NR<5), alkaline phosphatase
204 (NR 3–104 U/L), gamaglutamyltransferase 171 (NR
7–32 U/L), aspartataminotransferase 48 (NR 6–35 U/L),
alaninaminotransferase 119 (NR 6–35 U/L), fibrinogen
9.6 (NR 1–3.5 mmol/L) and D-dimer 527 (NR<192 mg/L).
All other biochemical and hematological findings were
within normal limits. Chest radiography showed bilat-
eral infiltrates of the lung pointing to pneumonia. The
patient was transferred to the department of pulmology.
Computer tomography (CT) of the chest confirmed bilat-
eral pneumonia. Fiber optic bronchoscopy demonstrated
only yellow secretion in tracheobronchal system. Micro-
biological, mycological and cytological findings of the
specimens obtained by bronchial washing were negative.
Mycobacteria Growth Indicator Tube test was negative.
All the hemocultures were negative too, the serological
tests on respiratory viruses and HIV as well. The radiog-
raphy of the right shoulder showed no local abnormali-
ties after surgery. On the initial combined antimicrobial
therapy the patient did not react. He remained high fe-
brile and developed small pleural effusion. The pleural
punction was performed. The cytological finding pointed
to the inflammation. Microbiological finding was nega-
tive. Control chest radiography showed bilateral pneu-
monia-like infiltrates (Figure 3) and CT showed progres-
sion of the disease and few nodular infiltrates were
observed pointing to possible metastasis process (Figure
4). CT guided transthoracal punction was performed –
cytological finding was typical for inflammation. Despite
changed antimicrobial therapy clinical worsening occur-
red and the patient died two weeks later. The autopsy
showed multiple metastases of the lung with multiple
small thromboemboli of the lung by tumor cells.
Discussion and Conclusion
Primary bone tumors are rare tumors, compared with
other malignant tumors9. The appearance of chondro-
sarcoma in our patient was in the age of 38 years and
that was very close to age over 40 years in which one half
of all chondrosarcoma occur1. Primary CS is the second
most common malignant tumor of bone10. The most af-
fected bones are the pelvis (31%), femur (21%) and shoul-
der girdle (13%)4,5. Chondrosarcomas of the proximal hu-
merus is an uncommon malignant bone tumor11. As in
our case, the most common presentation of the tumor is
local pain (81.4% of the cases) with radiological signs of
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Fig. 1. Chest radiograph before surgery appears normal.
Fig. 2. Tumor biopsy specimen shows chondrosarcoma grade II
that is infiltrating the bone and expanding to neighbor soft tissue.
Fig. 3. Chest radiograph shows bilateral pneumonia like
patchy consolidations.
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bone tumor12. Pain, which indicates active growth, is an
ominous sign of central cartilage lesion13. Fine needle as-
piration biopsy (FNAB) is the first step of the initial eval-
uation of the CS, especially in cases with classic clinical
and radiological findings14,15. A possible substitution can
be open surgical biopsy if the material provided by FNAB
is inadequate. It is not uncommon to make a mistake
grading the tumor in this phase of diagnosis and change
it to high-grade tumor at the final diagnosis. The same
CS, because of lack of experience, can be graded differ-
ently at different institutions, and some authors have de-
scribed even mistakes determining the type of the malig-
nant bone tumor before and after the surgery16. We think
that similar problems could be responsible for discrep-
ancy between pathohistological grade between an open
biopsy (CS grade I) an postoperative pathohystological
diagnosis (CS grade II). The importance of these mis-
takes can be illustrated by the fact that development of
metastases ranges from 0% in patients with grade I tu-
mor to 20% in grade II tumor, 60% in grade III tumor,
and 75% in patients with dedifferentiated CS17. Some re-
searches have proven that localization of the tumor, type
of surgery and duration of symptoms are of no prognostic
significance18. This makes histological grading even mo-
re important in predicting the clinical course of CS.
The development of metastases together with local re-
currence and subtype of CS have significant influence on
survival rate. Most commonly affected localizations with
metastases are lung, bones and visceral organs. In gen-
eral, CS shows slow biologic evolution, and metastases
usually develop one or more years after surgery. In a
study provided by Sheth this time ranged from 1 to 111
months17. Surgery with large tumor excision remains the
most reliable treatment option. Aside from the benefit,
surgical intervention means the risk of pulmonary tumor
embolism as in the case described by Newkirk, where
embolism occurred during operation19. Similar pathway
of tumor dissemination could happened in our case where
it is probably that the small tumor emboli disseminated
in the lungs during surgery or even postoperatively pro-
voking two weeks later multiple tumor metastases. We
did not find, however, any case in the literature where
the growth of metastases occurred so fast. Also, all the
results of the diagnostic procedures performed on our pa-
tient pointed to pneumonia, as a most possible postoper-
atively complication, and misled us in the treatment of
the patient. Therefore, even rare, such fulminant and
unusual course must be taken into consideration by ex-
perienced and cooperative team of specialists to prevent
any pitfalls in the diagnosis and treatment of the patient
with CS.
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Fig. 4. Transverse computer tomography scan (CT) of the chest
obtained during the fine needle aspiration biopsy (FNAB) shows
bilateral nodular consolidations representing metastases.
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CENTRALNI TIP HONDROSARKOMA S FULMINANTNIM TIJEKOM – PRIKAZ SLU^AJA
S A @ E T A K
Primarni hondrosarkom je rijetka zlo}udna novotvorina. Postoji pet tipova hondrosarkoma: centralni, periferni,
mezenhimalni, diferencirani i svjetlostani~ni. Klasi~ni hondrosarkomi su centralni (javljaju se u unutra{njosti kosti) ili
periferni (javljaju se na povr{ini kosti). Prikazan je slu~aj pacijenta s centralnim hondrosarkomom nadlakti~ne kosti
kod kojeg su se svega dva tjedna po operativnom zahvatu pojavile vi{estruke metastaze na plu}ima i mali tumorski
emboli u plu}ima koji su imitirali obostrane plu}ne upalne infiltrate. Zbog prethodno iznesenog, ovakav, do sada neopi-
san u literaturi, fulminantni tijek centralnog hondrosarkoma treba uzeti u razmatranje prilikom lije~enja pacijenata s
primarnim hondrosarkomom.
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